Pure Global
NCT04906109

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA-2803 in Healthy Subjects

A Randomized, Open-label, Single-dose, 2x2 Crossover Study to Compare the Safety/Tolerability and Pharmacokinetics Between and DA-2803 and Vemlidy® After Meal in Healthy Adults
Dong-A ST Co., Ltd.·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatitis B
Drug/Device/Intervention
Vemlidy Tab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Dong-A ST Co., Ltd.
Location
Seoul, South Korea
Timeline & enrollment
Phase
Phase 1
Start date
Jun 10, 2021
End date
Sep 30, 2021
Enrollment
96 participants
Primary outcome

AUCt of DA-2803, Vemlidy,Cmax of DA-2803, Vemlidy

Summary

This study is an open-label, randomized, single dose, crossover study to evaluate the
 pharmacokinetics, safety and tolerability of DA-2803 in healthy subjects

ICD-10 classifications
Acute hepatitis BAcute hepatitis B without delta-agent and without hepatic comaAcute delta-(super)infection in chronic hepatitis BChronic viral hepatitis B without delta-agentChronic viral hepatitis B without delta-agent : other and unspecified phase
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04906109
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04906109 through Pure Global AI's free database. This Phase 1 trial is sponsored by Dong-A ST Co., Ltd. and is currently Not yet recruiting. The study focuses on Hepatitis B. Target enrollment is 96 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.